Penumbra (PEN)
(Delayed Data from NYSE)
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Zacks News
Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
Penumbra (PEN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Penumbra (PEN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 14.29% and 0.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
by Zacks Equity Research
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal third-quarter revenues.
Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings
by Zacks Equity Research
Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.
Can RadNet's (RDNT) Service Fee Revenues Help Lift Q2 Earnings?
by Zacks Equity Research
RadNet's (RDNT) Imaging Center segment is likely to have gained from the increased reimbursement from commercial and capitated payors and strong procedure volumes in the second quarter of 2024.
Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.
Analysts Estimate Waters (WAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Waters (WAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
by Zacks Equity Research
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Play Henry Schein (HSIC) Ahead of Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is expected to deliver impressive sales in both its businesses in the second quarter of 2024, along with a steady pace of recovery from the cyber incident.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.
Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release
by Zacks Equity Research
Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.
Here's Why Penumbra (PEN) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings
by Zacks Equity Research
Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.
Will Patient Volumes Drive Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 performance is likely to gain from strong performances in its Acute Care Hospital Services and Behavioral Health Care Services segments.
Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Looking for a Growth Stock? 3 Reasons Why Penumbra (PEN) is a Solid Choice
by Zacks Equity Research
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
How Much Upside is Left in Penumbra (PEN)? Wall Street Analysts Think 34.22%
by Zacks Equity Research
The consensus price target hints at a 34.2% upside potential for Penumbra (PEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Holding Align Technology (ALGN) Stock Could Pay Off
by Zacks Equity Research
Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Penumbra (PEN) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GMED or PEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMED vs. PEN: Which Stock Is the Better Value Option?